Chinese pharma claims first Alzheimer’s drug approval since 2003

China’s drugs regulator has conditionally approved Shanghai Green Valley Pharmaceuticals’ Oligomannate to improve cognitive function in mild to moderate Alzheimer’s disease, the first novel drug approved to treat the condition since 2003.